



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/754410/2009
EMA/V/C/000153

Resporc FLU3 (*inactivated influenza-A virus / swine*)

An overview of Resporc FLU3 and why it is authorised in the EU

What is Resporc FLU3 and what is it used for?

Resporc FLU3 is a vaccine that contains 3 different strains of swine influenza A virus which have been inactivated (killed). Resporc FLU3 is a suspension for injection.

Resporc FLU3 is used to vaccinate pigs including pregnant sows over the age of 56 days against swine influenza in order to help them clinically but also to reduce the amount of virus present in the lungs. Resporc FLU3 is also used to vaccinate pregnant sows following their first immunisation by giving them one dose 14 days prior to farrowing in order that the sows milk contains enough antibodies to help protect the piglets against swine influenza for at least 33 days after birth.

How is Resporc FLU3 used?

The medicine can only be obtained with a prescription. For primary vaccination, piglets, gilts and sows are given 2 injections of one dose. A booster is possible at each stage of pregnancy and lactation. For more information about using Resporc FLU3, see the package leaflet or contact your veterinarian or pharmacist.

How does Resporc FLU3 work?

Resporc FLU3 is a vaccine. Vaccines work by 'teaching' the immune system (the body's natural defences) how to defend itself against a disease. Resporc FLU3 contains small amounts of a modified and then killed form of the pig's influenza virus that causes lesions and illness. The vaccine also contains 'adjuvants' to stimulate a better response. When a pig is given the vaccine, the immune system recognises the killed viruses as 'foreign' and makes antibodies against them. In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses. This protects the pigs against the disease.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



What benefits of Respiporc FLU3 have been shown in studies?

The effectiveness of Respiporc FLU3 has been studied in animals 56 days of age and older and in sows before and during pregnancy, and these studies document that the vaccine protects against swine influenza.

Use of the Respiporc FLU3 in pigs reduces clinical signs and reduces the amount of virus in the lungs after infection caused by swine influenza A virus.

What are the risks associated with Respiporc FLU3?

A slight swelling may occur after vaccination at the site of injection in a small number of pigs but this goes down within 2 days. Sometimes, a slight increase in the rectal temperature might occur after vaccination.

For the full list of side effects and restrictions of Respiporc FLU3, see the package leaflet.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

In case of accidental self-injection only a minor injection site reaction is expected. Safety information has been included in the summary of product characteristics and the package leaflet for Respiporc FLU3, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.

What is the withdrawal period in food-producing animals?

The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption. The withdrawal period for meat from pigs treated with Respiporc FLU3 is 'zero' days, which means that there is no mandatory waiting time.

Why is Respiporc FLU3 authorised in the EU?

The European Medicines Agency decided that Respiporc FLU3's benefits are greater than its risks and it can be authorised for use in the EU.

Other information about Respiporc FLU3

Respiporc FLU3 received a marketing authorisation valid throughout the EU on 14 January 2010.

Further information on Respiporc FLU3 can be found on the Agency's website:

ema.europa.eu/medicines/veterinary/EPAR/respiporc-flu3

This overview was last updated in 03-2020.